Bio-Techne Corp — Earnings Quality Grade F
TECH · Healthcare
Major red flags
Screening Summary
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 62 days, change -14 days YoY
AR growth -14.3% vs revenue growth 5.2%
Revenue 5.2%, CFFO -3.8%. Cash follows revenue
Expense Quality
Inventory 5.4% vs COGS 10.3%. Normal
CapEx growth -50.7% vs revenue 5.2%. Normal
SG&A/Gross Profit = 52.5%. Normal
Gross margin 64.8%, change -1.6pp. Stable
Cash Flow Quality
CFFO/NI = 3.92. Profits backed by cash
FCF $0.3B, FCF/NI = 3.50
Accruals ratio = -8.4%. Low accruals
Cash $0.2B covers only 37% of debt $0.4B
Balance Sheet Health
Goodwill+Intangibles $1.3B = 70% of equity. Over 50%
Debt/EBITDA = 2.0x. Healthy
Other assets grew 63.3% vs revenue 5.2%
Write-offs surged 267% YoY, = 110% of NI. Possible big bath
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -9% YoY. Normal
Manipulation Score
M-Score = -3.04 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-09